How to buy Takeda Pharmaceutical shares | TAK historical share price and analysis

How to buy Takeda Pharmaceutical shares

Own Takeda Pharmaceutical shares in just a few minutes.

Picture not described

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Takeda Pharmaceutical Company Limited is a drug manufacturers-specialty & generic business with stocks listed in the US. Takeda Pharmaceutical shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.

How to buy shares in Takeda Pharmaceutical

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Takeda Pharmaceutical. Find the share by name or ticker symbol: TAK. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Takeda Pharmaceutical reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Takeda Pharmaceutical, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Takeda Pharmaceutical. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Takeda Pharmaceutical share price

Use our graph to track the performance of TAK stocks over time.

Takeda Pharmaceutical shares at a glance

Information last updated 2021-04-16.
52-week rangeUS$15.3 - US$19.97
50-day moving average US$18.16
200-day moving average US$17.7547
Target priceUS$22.9
PE ratio 32.3112
Dividend yield US$180 (1046.51%)
Earnings per share (TTM) US$0.527

Compare share trading platforms to buy stock

Data updated regularly
Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
US$10 per month if there’s been no login for 12 months
US shares
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
$50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
CMC Markets Stockbroking
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Takeda Pharmaceutical stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Takeda Pharmaceutical under- or over-valued?

Valuing Takeda Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Takeda Pharmaceutical's P/E ratio

Takeda Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Takeda Pharmaceutical shares trade at around 32x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Takeda Pharmaceutical's PEG ratio

Takeda Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1247. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Takeda Pharmaceutical's EBITDA

Takeda Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$781.4 billion (£564.9 billion).

The EBITDA is a measure of a Takeda Pharmaceutical's overall financial performance and is widely used to measure a its profitability.

Takeda Pharmaceutical financials

Revenue TTM US$3,199.2 billion
Operating margin TTM 8.91%
Gross profit TTM US$2,201.5 billion
Return on assets TTM 1.41%
Return on equity TTM 3.8%
Profit margin 5.65%
Book value 1482.5015
Market capitalisation US$53.2 billion

TTM: trailing 12 months

Shorting Takeda Pharmaceutical shares

There are currently 9.4 million Takeda Pharmaceutical shares held short by investors – that's known as Takeda Pharmaceutical's "short interest". This figure is 43.3% up from 6.6 million last month.

There are a few different ways that this level of interest in shorting Takeda Pharmaceutical shares can be evaluated.

Takeda Pharmaceutical's "short interest ratio" (SIR)

Takeda Pharmaceutical's "short interest ratio" (SIR) is the quantity of Takeda Pharmaceutical shares currently shorted divided by the average quantity of Takeda Pharmaceutical shares traded daily (recently around 3.0 million). Takeda Pharmaceutical's SIR currently stands at 3.1. In other words for every 100,000 Takeda Pharmaceutical shares traded daily on the market, roughly 3100 shares are currently held short.

However Takeda Pharmaceutical's short interest can also be evaluated against the total number of Takeda Pharmaceutical shares, or, against the total number of tradable Takeda Pharmaceutical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Takeda Pharmaceutical's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Takeda Pharmaceutical shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Takeda Pharmaceutical shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Takeda Pharmaceutical.

Find out more about how you can short Takeda Pharmaceutical stock.

Takeda Pharmaceutical share dividends


Dividend payout ratio: 19.76% of net profits

Recently Takeda Pharmaceutical has paid out, on average, around 19.76% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.94% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Takeda Pharmaceutical shareholders could enjoy a 4.94% return on their shares, in the form of dividend payments. In Takeda Pharmaceutical's case, that would currently equate to about $180 per share.

While Takeda Pharmaceutical's payout ratio might seem low, this can signify that Takeda Pharmaceutical is investing more in its future growth.

Takeda Pharmaceutical's most recent dividend payout was on 14 December 2009. The latest dividend was paid out to all shareholders who bought their shares by 28 September 2020 (the "ex-dividend date").

Takeda Pharmaceutical share price volatility

Over the last 12 months, Takeda Pharmaceutical's shares have ranged in value from as little as US$15.3 up to US$19.97. A popular way to gauge a stock's volatility is its "beta".

TAK.US volatility(beta: 1.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Takeda Pharmaceutical's is 1.1678. This would suggest that Takeda Pharmaceutical's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Takeda Pharmaceutical overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site